SILVER SPRING, Md., and DURHAM, N.C. — United Therapeutics Corporation has appointed Kevin J. Tracey, M.D., to its board of directors, effective January 21, 2026, adding a senior physician-scientist with extensive experience in inflammation research and bioelectronic medicine.
Dr. Tracey is president and chief executive officer of The Feinstein Institutes for Medical Research, where he also holds the Karches Family Distinguished Chair in Medical Research. He serves as a professor of molecular medicine and neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and as executive vice president for research at Northwell Health.
His research has focused on the interaction between the nervous and immune systems, including the discovery and mapping of neural circuits that regulate immunity. Dr. Tracey is also credited with identifying the therapeutic mechanism of monoclonal anti-TNF antibodies, now widely used to treat inflammatory diseases. In addition to his academic work, he has co-founded several biotechnology companies, including SetPoint Medical, which focuses on bioelectronic medicine.
Martine Rothblatt, Ph.D., chairperson and chief executive officer of United Therapeutics, said Dr. Tracey’s scientific and entrepreneurial background would add depth to the board’s oversight.
“Dr. Tracey brings a rare combination of scientific leadership, entrepreneurial experience, and groundbreaking research expertise,” Rothblatt said. “His work in inflammation and bioelectronic medicine, along with his experience leading major research institutions, positions him to help guide United Therapeutics as it advances its mission.”
Dr. Tracey said he looks forward to contributing to the company’s work in rare disease therapeutics and organ manufacturing technologies.
“I am delighted to join United Therapeutics’ board of directors as the company advances its therapeutic pipeline for rare pulmonary diseases and its organ manufacturing development programs,” he said. “I look forward to supporting its patient-driven mission.”
Christopher Causey, chair of the board’s nominating and governance committee, said the appointment reflects the company’s ongoing efforts to refresh and broaden board expertise.
“Dr. Tracey brings valuable scientific insight and operational healthcare experience to our board,” Causey said.
United Therapeutics is a public benefit corporation focused on developing therapies for rare diseases and technologies aimed at expanding the availability of transplantable organs.
